{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:37:51Z","timestamp":1790289471698,"version":"4.1.0"},"reference-count":112,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Because of the chronic course of the disease, clinicians managing IBD frequently encounter patients with a prior or newly diagnosed cancer. This can be related to the specific background cancer risk in that subject, aging, familial\/genetic factors, or ongoing chronic inflammation. However, a potential influence of some therapeutic agents should also be considered. This setting, in the absence of controlled trials and few open series reports available, raises issues such as correct screening, prevention, and surveillance, but also eventual modification or adaptation of the medical management. Methods and Results: Few consensus guidelines and studies are available on the management of IBD patients with a history of cancer, and therefore, we aim to review the recommendations of the current guidelines and the evidence reported in the most recent real-world cohorts. Conclusions: This review will offer (a) an understanding of the background of cancer risk in IBD patients; (b) analysis and discussion of the risk of cancer related to IBD therapy; and, finally, (c) some clues for the management of IBD in patients with a previous or current history of cancer.<\/jats:p>","DOI":"10.3390\/cancers17213475","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:50:19Z","timestamp":1761785419000},"page":"3475","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of Inflammatory Bowel Disease with History of Cancer"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0082-892X","authenticated-orcid":false,"given":"Vito","family":"Annese","sequence":"first","affiliation":[{"name":"Unit of Gastroenterology, IRCCS San Donato Policlinic, San Donato Milanese, 20097 Milan, Italy"},{"name":"Department of Gastroenterology and Endoscopy, Vita-Salute University San Raffaele, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzio","family":"Parisi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Therapy, University of Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Cinque","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology, IRCCS San Donato Policlinic, San Donato Milanese, 20097 Milan, Italy"},{"name":"Department of Clinical Medicine and Surgery, Gastroenterology Unit, University Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cappellini","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Therapy, University of Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Biamonte","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology, IRCCS San Donato Policlinic, San Donato Milanese, 20097 Milan, Italy"},{"name":"Department of Gastroenterology and Endoscopy, Vita-Salute University San Raffaele, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9395-5468","authenticated-orcid":false,"given":"Giuseppe","family":"Dell\u2019Anna","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology, IRCCS San Donato Policlinic, San Donato Milanese, 20097 Milan, Italy"},{"name":"Department of Gastroenterology and Endoscopy, Vita-Salute University San Raffaele, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Gloria Giulia","family":"Testoni","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology, IRCCS San Donato Policlinic, San Donato Milanese, 20097 Milan, Italy"},{"name":"Department of Gastroenterology and Endoscopy, Vita-Salute University San Raffaele, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Annunziata","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology, IRCCS San Donato Policlinic, San Donato Milanese, 20097 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","article-title":"European evidence-based consensus: Inflammatory bowel disease and malignancies","volume":"9","author":"Annese","year":"2015","journal-title":"J. Crohns Colitis"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ecco-jcc\/jjac187","article-title":"ECCO Guidelines on inflammatory bowel disease and malignancies","volume":"17","author":"Gordon","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00432-020-03496-0","article-title":"Inflammatory bowel disease and risk of gastric, small bowel and colorectal cancer: A meta-analysis of 26 observational studies","volume":"147","author":"Wan","year":"2021","journal-title":"J. Cancer Res. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(19)32545-0","article-title":"Colorectal cancer in ulcerative colitis: A Scandinavian population-based cohort study","volume":"395","author":"Olen","year":"2020","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1111\/j.1572-0241.2005.00287.x","article-title":"Increased risk of intestinal cancer in Crohn\u2019s disease: A meta-analysis of population-based cohort studies","volume":"100","author":"Jess","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cgh.2012.01.010","article-title":"Risk of colorectal cancer in patients with ulcerative colitis: A meta-analysis of population-based cohort studies","volume":"10","author":"Jess","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/apt.12651","article-title":"Systematic review with meta-analysis: The declining risk of colorectal cancer in ulcerative colitis","volume":"39","author":"Chaparro","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.14309\/ajg.0000000000002900","article-title":"A population-based matched cohort study of digestive system cancer incidence and mortality in individuals with and without inflammatory bowel disease","volume":"119","author":"Murphy","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1053\/j.gastro.2012.04.016","article-title":"Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years","volume":"143","author":"Jess","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/gast.1996.v110.pm8566577","article-title":"Risk and natural history of colonic neoplasia in patients with primary Sclerosing cholangitis and ulcerative colitis","volume":"110","author":"Brentnall","year":"1996","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10350-006-0848-z","article-title":"The risk of cancer in patients with Crohn\u2019s disease","volume":"50","author":"Reese","year":"2007","journal-title":"Dis. Colon. Rectum"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/MIB.0b013e3182802af7","article-title":"Five-year mortality in colorectal cancer patients with ulcerative colitis or Crohn\u2019s disease: A nationwide population-based cohort study","volume":"19","author":"Ording","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1093\/ibd\/izz088","article-title":"Age-Related survival differences in patients with inflammatory bowel disease-associated colorectal cancer: A population-based cohort study","volume":"25","author":"Bogach","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2468-1253(20)30005-4","article-title":"Colorectal cancer in Crohn\u2019s disease: A Scandinavian population-based cohort study","volume":"5","author":"Olen","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s11605-010-1402-9","article-title":"Intestinal cancer risk in Crohn\u2019s disease: A meta-analysis","volume":"15","author":"Laukoetter","year":"2011","journal-title":"J. Gastrointest. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.cgh.2015.08.042","article-title":"Risk of neoplasia after colectomy in patients with inflammatory bowel disease: A systematic review and meta-analysis","volume":"14","author":"Derikx","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient Age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis","volume":"152","author":"Weismuller","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cgh.2020.08.015","article-title":"The risk of extraintestinal cancer in inflammatory bowel disease: A systematic review and meta-analysis of population-based cohort studies","volume":"19","author":"Lo","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e220595","DOI":"10.1001\/jamanetworkopen.2022.0595","article-title":"Development of cancer among patients with pediatric-onset inflammatory bowel disease: A meta-analysis of population-based study","volume":"5","author":"Elmahdi","year":"2022","journal-title":"JAMA New Open"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/ajg.2009.760","article-title":"Risk of extra-intestinal cancer in inflammatory bowel disease: Meta-analysis of population-based cohort studies","volume":"105","author":"Pedersen","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.crohns.2011.11.005","article-title":"Fistulizing pattern in Crohn\u2019s disease and pancolitis in ulcerative colitis are independent risk factors for cancer: A single center cohort study","volume":"6","author":"Biancone","year":"2012","journal-title":"J. Crohns Colitis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/ibd.20959","article-title":"Lack of association between cervical dysplasia and IBD: A large case-control study","volume":"15","author":"Lees","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/gut.2004.051771","article-title":"Risk of haematopoietic cancer in patients with inflammatory bowel disease","volume":"54","author":"Askling","year":"2005","journal-title":"Gut"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2009.11.024","article-title":"Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease","volume":"8","author":"Long","year":"2010","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/ibd\/izab336","article-title":"Inflammatory Bowel Disease Risk Variants Are Associated with an Increased Risk of Skin Cancer","volume":"28","author":"Cushing","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1053\/j.gastro.2011.07.039","article-title":"Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease","volume":"141","author":"Singh","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11894-012-0310-4","article-title":"Clinical outcomes and management of inflammatory bowel disease in the older patient","volume":"15","author":"Ha","year":"2013","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/sj.bjc.6605733","article-title":"Skin cancers associated with autoimmune conditions among elderly adults","volume":"103","author":"Lanoy","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1093\/jcag\/gwad006","article-title":"The 2023 impact of inflammatory bowel disease in Canada: Cancer and IBD","volume":"6","author":"Murphy","year":"2023","journal-title":"J. Canad. Assoc. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/apt.15692","article-title":"Systematic review with meta-analysis: Biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease","volume":"51","author":"Piovani","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_31","first-page":"CD000279","article-title":"Strategies for detecting colon cancer in patients with inflammatory bowel disease","volume":"19","author":"Bye","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1007\/s10620-021-07151-7","article-title":"Periodic colonoscopies are associated with improved survival and prognosis of colorectal cancer in ulcerative colitis","volume":"67","author":"Narula","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"ref_33","first-page":"e289","article-title":"Frequency of surveillance and impact of surveillance colonoscopies in patients with ulcerative colitis who developed colorectal cancer","volume":"17","author":"Cole","year":"2018","journal-title":"Clin. Color. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"483","DOI":"10.14309\/ajg.0000000000000117","article-title":"Surveillance colonscopy for ulcerative colitis-associated colorectal cancer offers better overall survival in real-world surgically resected cases","volume":"114","author":"Hata","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_35","first-page":"CD000279","article-title":"Strategies for detecting colon cancer and\/or dysplasia in patients with inflammatory bowel disease","volume":"2","author":"Collins","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1572-0241.1998.00314.x","article-title":"Performing a cost-effectiveness analysis: Surveillance of patients with ulcerative colitis","volume":"93","author":"Provenzale","year":"1998","journal-title":"Am. J. Gastroenterol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/gut.48.4.526","article-title":"The risk of colorectal cancer in ulcerative colitis: A meta-analysis","volume":"48","author":"Eaden","year":"2001","journal-title":"Gut"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/gut.2009.179804","article-title":"Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002)","volume":"59","author":"Cairns","year":"2010","journal-title":"Gut"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.crohns.2013.09.016","article-title":"European evidence based consensus for endoscopy in inflammatory bowel disease","volume":"7","author":"Annese","year":"2013","journal-title":"J. Crohns Colitis"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"East, J.E., Gordon, M., Nigam, G.B., Sinopoulou, V., Bateman, A.C., Din, S., Iacucci, M., Kabir, M., Lamb, C.A., and Wilson, A. (Gut, 2025). British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease, Gut, Online ahead of print.","DOI":"10.1136\/gutjnl-2025-335023"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"523","DOI":"10.21873\/invivo.13470","article-title":"Occurrence of colorectal cancer after a negative colonoscopy in patients with inflammatory bowel disease: A systematic review and meta-analysis","volume":"38","author":"Scotti","year":"2024","journal-title":"In Vivo"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/01.MIB.0000158951.54388.3a","article-title":"Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease","volume":"11","author":"Toruner","year":"2005","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/apt.15493","article-title":"Systematic review with network meta-analysis: Endoscopic techniques for dysplasia surveillance in inflammatory bowel disease","volume":"50","author":"Iannone","year":"2019","journal-title":"Alim. Pharmacol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1136\/gutjnl-2016-312043","article-title":"Expert opinions and scientific evidence for colonoscopy key performance indicators","volume":"65","author":"Rees","year":"2016","journal-title":"Gut"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1365-2036.2010.04525.x","article-title":"Meta-analysis: The diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease","volume":"33","author":"Subramanian","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1463-1318.2010.02505.x","article-title":"The diagnostic accuracy of chromoendoscopy for dysplasia in ulcerative colitis: Meta-analysis of six randomized controlled trials","volume":"14","author":"Wu","year":"2012","journal-title":"Colon. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/gutjnl-2017-315235","article-title":"Advanced endoscopic techniques in the assessment of inflammatory bowel disease: New technology, new era","volume":"68","author":"Iacucci","year":"2019","journal-title":"Gut"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.cgh.2024.11.008","article-title":"Comparative efficacy and safety of endoscopic modalities for colorectal cancer screening in inflammatory bowel disease: A systematic review and network meta-analysis","volume":"23","author":"Sinopoulou","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.cgh.2024.02.014","article-title":"Dynamic prediction of advanced colorectal neoplasia in inflammatory bowel disease","volume":"22","author":"Wijnands","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-4632.2011.05205.x","article-title":"Smoking and the skin","volume":"51","author":"Ortiz","year":"2012","journal-title":"Int. J. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R","article-title":"Melanoma and sun exposure: An overview of published studies","volume":"73","author":"Elwood","year":"1997","journal-title":"Int. J. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1126\/science.1114233","article-title":"Azathioprine and UVA light generate mutagenic oxidative DNA damage","volume":"309","author":"Perrett","year":"2005","journal-title":"Science"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jgh.14533","article-title":"Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: A systematic review and meta-analysis","volume":"34","author":"Huang","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamadermatol.2020.1300","article-title":"Melanoma risk in patients treated with biologic therapy for common inflammatory diseases: A systematic review and meta-analysis","volume":"156","author":"Esse","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/ibd\/izac171","article-title":"Risks of Melanoma and Nonmelanoma Skin Cancers Pre- and Post-Inflammatory Bowel Disease Diagnosis","volume":"29","author":"Narous","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1158\/0008-5472.CAN-09-0451","article-title":"Mutagenicity and potential carcinogenetic of thiopurine treatment in patients with inflammatory bowel disease","volume":"69","author":"Nguyen","year":"2009","journal-title":"Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A Systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease","volume":"9","author":"Kotlyar","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.cgh.2014.02.026","article-title":"Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease","volume":"12","author":"Lopez","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1053\/j.gastro.2013.09.035","article-title":"Lymphoma: The bete noire of the long term use of thiopurines in adult and elderly patients with inflammatory bowel disease","volume":"145","author":"Beaugerie","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ajg.2013.451","article-title":"Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: A meta-analysis","volume":"109","author":"Ariyaratnam","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Khosrotehrani","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cgh.2013.04.033","article-title":"Inflammatory bowel disease is associated with an increased risk of melanoma: A systematic review and meta-analysis","volume":"12","author":"Singh","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"jjaf091","DOI":"10.1093\/ecco-jcc\/jjaf091","article-title":"Cancer incidence in patients with ulcerative colitis na\u00efve to or treated with thiopurines and targeted therapies\u2014A cohort study 2007 to 2022 with comparison to the general population","volume":"19","author":"Everhov","year":"2025","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.cgh.2024.08.006","article-title":"Thiopurines and the risk of cancer in patients with inflammatory bowel disease and reference individuals without inflammatory bowel disease: A Danish nationwide cohort study (1996\u20132018)","volume":"23","author":"Wewer","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-alpha antagonists and risk of cancer in patent with inflammatory bowel disease","volume":"311","author":"Pasternak","year":"2014","journal-title":"JAMA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/apt.12624","article-title":"Systematic review with meta-analysis: Malignancies with antitumour necrosis factor-alpha therapy in inflammatory bowel disease","volume":"39","author":"Williams","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/j.gastro.2013.12.025","article-title":"Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn\u2019s disease","volume":"146","author":"Osterman","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: A systematic review and network meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2013.441","article-title":"Drug therapies and the risk of malignancy in Crohn\u2019s disease: Results from the TREAT registry","volume":"109","author":"Lichtenstein","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/ajg.2011.283","article-title":"Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease","volume":"106","author":"Herrinton","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/apt.16050","article-title":"Systematic review with meta-analysis: Comparative risk of lymphoma with anti-tumour necrosis factor agents and\/or thiopurines in patients with inflammatory bowel disease","volume":"52","author":"Chupin","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1517\/14740338.2015.1063612","article-title":"Safety of vedolizumab in the treatment of Crohn\u2019s disease and ulcerative colitis","volume":"14","author":"Hagan","year":"2015","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/ecco-jcc\/jjad043","article-title":"Effectiveness and safety of vedolizumab in inflammatory bowel disease: A comprehensive meta-analysis of observational studies","volume":"17","author":"Macaluso","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/ecco-jcc\/jjae013","article-title":"Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn\u2019s Disease and 4 Years in Ulcerative Colitis","volume":"18","author":"Ghosh","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/jdv.13611","article-title":"Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry [PSOLAR]","volume":"30","author":"Menter","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytteberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Bezzio, C., Vernero, M., Ribaldone, D.G., Alimenti, E., Manes, G., and Saibeni, S. (2024). Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis. Cancers, 15.","DOI":"10.3390\/cancers15082197"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s12325-023-02732-6","article-title":"Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials","volume":"41","author":"Mysler","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: A meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Bernardi, F., Faggiani, I., Parigi, T.L., Zilli, A., Allocca, M., Furfaro, F., Peyrin-Biroulet, L., Danese, S., and D\u2019Amico, F. (2025). JAK inhibitors and risk of cancer in IBD patients. Cancers, 17.","DOI":"10.3390\/cancers17111795"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/ecco-jcc\/jjad146","article-title":"Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension","volume":"18","author":"Danese","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): Two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/ueg2.70026","article-title":"Sphingosine-1-Phosphate Receptor Modulators for the Treatment of Ulcerative Colitis: A Narrative Review Focusing on Safety","volume":"13","author":"Fantini","year":"2025","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/ecco-jcc\/jjab093","article-title":"Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn\u2019s Disease: Results from the Phase 2 Open-Label Extension Study","volume":"15","author":"Ferrante","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/ibd\/izae024","article-title":"Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study","volume":"30","author":"Sands","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1007\/s12325-023-02568-0","article-title":"Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review","volume":"40","author":"Blauvelt","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.cgh.2022.09.018","article-title":"I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease","volume":"21","author":"Rahier","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_90","unstructured":"Curtis, R.E., Freedman, D.M., Ron, E., Ries, L.A.G., Hacker, D.G.B.K., Tucker, M.A., and Fraumeni, J.F. (2006). New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973\u20132000, National Cancer Institute. NIH Publ. No. 05-5302."},{"key":"ref_91","first-page":"14","article-title":"Evaluation of transplant candidates with pre-existing malignancies","volume":"2","author":"Penn","year":"1997","journal-title":"Ann. Transplant."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/00007890-199304000-00011","article-title":"The effect of immunosuppression on preexisting cancers","volume":"55","author":"Penn","year":"1993","journal-title":"Transplantation"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2174\/1389450115666140821113330","article-title":"Management of inflammatory bowel disease patients with a cancer history","volume":"15","author":"Beaugerie","year":"2014","journal-title":"Curr. Drug Targets"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MCG.0000000000000865","article-title":"Rate cancer recurrence among individuals exposed to antitumor necrosis factor therapy: A systematic review and meta-analysis of observational studies","volume":"53","author":"Micic","year":"2019","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.gastro.2016.03.037","article-title":"Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: A systematic review and meta-analysis","volume":"151","author":"Shelton","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cgh.2020.10.007","article-title":"Vedolizumab or tumor necrosis factor antagonist use and risk of new or recurrent cancer in patients with inflammatory bowel disease with prior malignancy: A retrospective cohort study","volume":"20","author":"Vedamurthy","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/ecco-jcc\/jjac061","article-title":"Comparative risk of incident cancer in patients with inflammatory bowel disease with prior non-digestive malignancy according to immunomodulator: A multicenter cohort study","volume":"16","author":"Poullenot","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/ibd\/izac035","article-title":"Ustekinumab and vedolizumab are not associated with subsequent cancer in IBD patients with prior malignancy","volume":"28","author":"Hong","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cgh.2023.07.027","article-title":"Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis","volume":"22","author":"Gupta","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10238-025-01738-4","article-title":"Risk of new or recurrent cancer during treatment with biologics in patients with immune-mediated inflammatory disease and previous cancers: A meta-analysis","volume":"219","author":"Isufi","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.cgh.2024.09.034","article-title":"Risk of incident cancer in patients with inflammatory bowel disease with prior breast cancer: A multicenter cohort study","volume":"23","author":"Kirchgesner","year":"2025","journal-title":"Clin. Gastroent. Hepatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cgh.2024.05.006","article-title":"Safety of immunosuppression in a prospective cohort of inflammatory bowel disease with a history of cancer: SAPPHIRE registry","volume":"23","author":"Itzkowitz","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1007\/s10620-025-09128-2","article-title":"Radiation Therapy for Abdominal or Pelvic Cancer Treatment in Patients with Inflammatory Bowel Disease: A Systematic Review","volume":"70","author":"Hayek","year":"2025","journal-title":"Dig. Dis. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.cgh.2019.06.042","article-title":"Hormone therapy for cancer is a risk factor for relapse of inflammatory bowel diseases","volume":"18","author":"Axelrad","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/ecco-jcc\/jjad010","article-title":"Systematic review with meta-analysis: The impact of cancer treatments on the disease activity of inflammatory bowel disease","volume":"17","author":"Grimsdottir","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Ferretti, F., Cannatelli, R., Maconi, G., and Ardizzone, S. (2023). Therapeutic management of adults with inflammatory bowel disease and malignancies: A clinical challenge. Cancers, 15.","DOI":"10.3390\/cancers15020542"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Conceicao, D., Saraiva, M.R., Rosa, I., and Claro, I. (2023). Inflammatory bowel disease treatment in cancer patients\u2014A comprehensive review. Cancers, 13.","DOI":"10.3390\/cancers15123130"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Wetwittayakhlang, P., Tselekouni, P., Al-Jabri, R., Bessissow, T., and Lakatos, P.L. (2023). The optimal management of inflammatory bowel disease in patients with cancer. J. Clin. Med., 12.","DOI":"10.3390\/jcm12062432"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Poullenot, F., and Laharie, D. (2023). Management of inflammatory bowel disease in patients with current or past malignancy. Cancers, 15.","DOI":"10.3390\/cancers15041083"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Faggiani, I., Bencardino, S., Allocca, M., Furfaro, F., Zilli, A., Parigi, T.L., Cicerone, C., Solitano, V., Peyrin-Biroulet, L., and Danese, S. (2025). Management of patients with IBD and history of cancers. Cancers, 17.","DOI":"10.3390\/cancers17071057"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.cgh.2024.03.032","article-title":"AGA clinical practice update on management of inflammatory bowel disease in patients with malignancy: Commentary","volume":"22","author":"Axelrad","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.cgh.2023.01.002","article-title":"Comparative safety of biologic agents in patients with inflammatory bowel disease with active or recent malignancies: A multi-center cohort study","volume":"21","author":"Holmer","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3475\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:00:02Z","timestamp":1761786002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":112,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["cancers17213475"],"URL":"https:\/\/doi.org\/10.3390\/cancers17213475","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]}}}